quinazolines has been researched along with pp242 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JJ; Fang, ZG; Lin, DJ; Liu, LL; Liu, Q; Long, ZJ; Wang, LX; Wang, SW; Xu, DF; Yan, M; Zheng, FM | 1 |
| Becker, MN; Copland, JA; Kreinest, PA; Marlow, LA; Vonroemeling, CA; Williams, CR; Wu, KJ | 1 |
| Amin, DN; Gulizia, N; Moasser, MM; Ruiz-Saenz, A | 1 |
| Ebata, T; Ishiwata, T; Iwama, A; Iwasawa, S; Koide, S; Kurimoto, R; Sekine, I; Tada, Y; Takiguchi, Y; Tatsumi, K | 1 |
4 other study(ies) available for quinazolines and pp242
| Article | Year |
|---|---|
Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Aurora Kinases; Benzamides; Cell Line, Tumor; Deoxyglucose; Gene Expression Regulation, Neoplastic; Glucose; Glycolysis; HL-60 Cells; Humans; Indoles; Lactic Acid; Leukemia, Myeloid, Acute; Piperazines; Polyploidy; Purines; Quinazolines; Sequestosome-1 Protein; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; U937 Cells | 2013 |
The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.
Topics: Aged; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Indoles; Lapatinib; Male; Purines; Quinazolines; Tissue Array Analysis; TOR Serine-Threonine Kinases; Triazines; Urinary Bladder Neoplasms | 2014 |
Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Imidazoles; Indoles; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2015 |
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cell Survival; Cisplatin; Dimethyl Sulfoxide; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lung Neoplasms; Metformin; Mutation; Purines; Quinazolines; Transforming Growth Factor beta | 2016 |